| Analysis |
Quality |
Hyps |
Surviving |
Orthogonality |
Date |
| Lipid raft composition changes in synaptic ne |
0.950 |
0 |
0 |
— |
2026-04-28 |
| Senescent cell clearance as neurodegeneration |
0.950 |
0 |
0 |
— |
2026-04-28 |
| Circuit-level neural dynamics in neurodegener |
0.950 |
0 |
0 |
— |
2026-04-28 |
| Circuit-level neural dynamics in neurodegener |
0.950 |
0 |
0 |
— |
2026-04-28 |
| Circuit-level neural dynamics in neurodegener |
0.651 |
0 |
0 |
— |
2026-04-27 |
| Epigenetic reprogramming in aging neurons |
0.463 |
0 |
0 |
— |
2026-04-27 |
| What is the temporal sequence of TREM2 signal |
0.595 |
0 |
0 |
— |
2026-04-27 |
| How does SYNGAP1, a 'synaptic' protein, funct |
0.712 |
0 |
0 |
— |
2026-04-27 |
| Circuit-level neural dynamics in neurodegener |
0.707 |
0 |
0 |
— |
2026-04-27 |
| Circuit-level neural dynamics in neurodegener |
0.867 |
0 |
0 |
— |
2026-04-27 |
| Circuit-level neural dynamics in neurodegener |
0.479 |
0 |
0 |
— |
2026-04-27 |
| What determines the specificity of RNA-protei |
0.579 |
0 |
0 |
— |
2026-04-27 |
| Cell type vulnerability in Alzheimers Disease |
0.115 |
0 |
0 |
— |
2026-04-27 |
| Cell type vulnerability in Alzheimers Disease |
0.425 |
0 |
0 |
— |
2026-04-27 |
| Cell type vulnerability in Alzheimers Disease |
0.479 |
0 |
0 |
— |
2026-04-27 |
| Trans-synaptic tau spreading and propagation |
0.344 |
0 |
0 |
— |
2026-04-27 |
| What molecular mechanisms drive microglial se |
0.459 |
0 |
0 |
— |
2026-04-27 |
| Circuit-level neural dynamics in neurodegener |
0.543 |
0 |
0 |
— |
2026-04-27 |
| Cell type vulnerability in Alzheimers Disease |
0.467 |
0 |
0 |
— |
2026-04-27 |
| SEA-AD Single-Cell Analysis: Cell-Type Vulner |
0.211 |
0 |
0 |
— |
2026-04-27 |
| Circuit-level neural dynamics in neurodegener |
0.187 |
0 |
0 |
— |
2026-04-27 |
| Circuit-level neural dynamics in neurodegener |
0.400 |
1 |
1 |
— |
2026-04-27 |
| Circuit-level neural dynamics in neurodegener |
0.500 |
1 |
1 |
— |
2026-04-27 |
| Lipid raft composition changes in synaptic ne |
0.500 |
1 |
1 |
— |
2026-04-27 |
| What genetic risk factors predispose individu |
0.500 |
1 |
1 |
— |
2026-04-27 |
| Senescent cell clearance as neurodegeneration |
0.440 |
1 |
1 |
— |
2026-04-27 |
| Circuit-level neural dynamics in neurodegener |
0.540 |
1 |
1 |
— |
2026-04-27 |
| Circuit-level neural dynamics in neurodegener |
0.650 |
1 |
1 |
— |
2026-04-27 |
| Cell type vulnerability in Alzheimers Disease |
0.520 |
0 |
0 |
— |
2026-04-27 |
| Cell type vulnerability in Alzheimers Disease |
0.720 |
0 |
0 |
— |
2026-04-27 |
| RNA binding protein dysregulation across ALS |
0.490 |
1 |
1 |
— |
2026-04-27 |
| What are the mechanisms by which gut microbio |
0.480 |
1 |
1 |
— |
2026-04-27 |
| Circuit-level neural dynamics in neurodegener |
0.600 |
1 |
1 |
— |
2026-04-27 |
| Epigenetic reprogramming in aging neurons |
0.460 |
1 |
1 |
— |
2026-04-27 |
| Circuit-level neural dynamics in neurodegener |
0.540 |
1 |
1 |
— |
2026-04-27 |
| Lipid raft composition changes in synaptic ne |
0.400 |
1 |
1 |
— |
2026-04-27 |
| Senolytic therapy for age-related neurodegene |
0.400 |
1 |
1 |
— |
2026-04-27 |
| Lipid raft composition changes in synaptic ne |
0.400 |
1 |
1 |
— |
2026-04-27 |
| What amyloid threshold level is required for |
0.500 |
1 |
1 |
— |
2026-04-26 |
| TREM2 agonism vs antagonism in DAM microglia |
0.500 |
1 |
1 |
— |
2026-04-26 |
| TREM2 agonism vs antagonism in DAM microglia |
0.500 |
1 |
1 |
— |
2026-04-26 |
| Circuit-level neural dynamics in neurodegener |
0.500 |
1 |
1 |
— |
2026-04-26 |
| Circuit-level neural dynamics in neurodegener |
0.500 |
1 |
1 |
— |
2026-04-26 |
| Senescent cell clearance as neurodegeneration |
0.500 |
1 |
1 |
— |
2026-04-26 |
| Circuit-level neural dynamics in neurodegener |
0.500 |
1 |
1 |
— |
2026-04-26 |
| Senescent cell clearance as neurodegeneration |
0.500 |
1 |
1 |
— |
2026-04-26 |
| Senescent cell clearance as neurodegeneration |
0.500 |
1 |
1 |
— |
2026-04-26 |
| Does tau dendritic missorting persist indepen |
0.646 |
7 |
5 |
— |
2026-04-25 |
| Does pericyte senescence drive BBB breakdown |
0.677 |
6 |
6 |
— |
2026-04-25 |
| What determines the temporal sequence of chol |
0.651 |
7 |
5 |
— |
2026-04-25 |
| Does C1q function differ based on subcellular |
0.680 |
6 |
6 |
— |
2026-04-25 |
| Do physiological concentrations of SCFAs (μM |
0.630 |
6 |
5 |
— |
2026-04-25 |
| Do pathogenic LRRK2 mutations amplify volume- |
0.742 |
5 |
5 |
— |
2026-04-25 |
| Does APOE4's reduced lipid-binding directly m |
0.582 |
6 |
3 |
— |
2026-04-25 |
| Allen Mouse Brain Aging Atlas: cross-age gene |
1.000 |
3 |
3 |
— |
2026-04-24 |
| Blood-brain barrier tight junction disruption |
0.760 |
0 |
0 |
— |
2026-04-23 |
| Senescent cell clearance as neurodegeneration |
0.810 |
0 |
0 |
— |
2026-04-23 |
| What are the mechanisms by which gut microbio |
0.824 |
5 |
5 |
— |
2026-04-22 |
| Synaptic pruning by microglia in neurodegener |
0.676 |
7 |
7 |
— |
2026-04-22 |
| Entorhinal cortex layer II vulnerability in A |
0.779 |
7 |
7 |
— |
2026-04-22 |
| Cell type vulnerability debate in Alzheimer's |
0.753 |
7 |
6 |
— |
2026-04-22 |
| Gap 006 analysis (archived stub) |
0.789 |
7 |
7 |
— |
2026-04-22 |
| Blood-brain barrier antibody transport mechan |
0.820 |
7 |
6 |
— |
2026-04-22 |
| APOE4 targeting in neurodegeneration |
0.823 |
4 |
4 |
— |
2026-04-22 |
| Investigate prion-like spreading of tau patho |
0.729 |
7 |
7 |
— |
2026-04-22 |
| epigenetic reprogramming aging neurons |
0.669 |
7 |
7 |
— |
2026-04-22 |
| APOE4-driven lipid metabolism dysregulation i |
0.780 |
7 |
7 |
— |
2026-04-22 |
| Trans-synaptic tau spreading and propagation |
0.776 |
7 |
7 |
— |
2026-04-22 |
| Investigate mechanisms of epigenetic reprogra |
0.790 |
7 |
7 |
— |
2026-04-22 |
| Lysosomal dysfunction and cathepsin leakage i |
0.763 |
7 |
7 |
— |
2026-04-22 |
| How do disease-associated mutations in G3BP1 |
0.693 |
7 |
4 |
— |
2026-04-22 |
| How do regional, age, and sex-dependent diffe |
0.730 |
7 |
6 |
— |
2026-04-22 |
| Can IGFBPL1 therapeutics effectively cross th |
0.691 |
7 |
4 |
— |
2026-04-22 |
| What is the therapeutic window between tau pr |
0.746 |
5 |
4 |
— |
2026-04-22 |
| How can senescent microglia be molecularly di |
0.724 |
7 |
7 |
— |
2026-04-22 |
| What molecular mechanisms mediate SPP1-induce |
0.704 |
7 |
4 |
— |
2026-04-22 |
| What biomarkers can reliably detect microglia |
0.754 |
7 |
7 |
— |
2026-04-22 |
| How do pathological stress granules in neurod |
0.746 |
7 |
5 |
— |
2026-04-22 |
| How do pathological stress granules transitio |
0.843 |
7 |
7 |
— |
2026-04-22 |
| What molecular mechanisms drive microglial se |
0.794 |
7 |
7 |
— |
2026-04-22 |
| What is the optimal therapeutic window for mi |
0.628 |
7 |
5 |
— |
2026-04-22 |
| Can chaperone enhancement approaches overcome |
0.729 |
7 |
5 |
— |
2026-04-22 |
| Do APOE4-driven senescent astrocytes cause ne |
0.763 |
7 |
7 |
— |
2026-04-22 |
| How do perivascular cells specifically recogn |
0.667 |
7 |
3 |
— |
2026-04-22 |
| How does controlled lysosomal membrane permea |
0.606 |
7 |
4 |
— |
2026-04-21 |
| Does SPP1-mediated synaptic engulfment repres |
0.685 |
7 |
5 |
— |
2026-04-21 |
| How does TRIM21-mediated K63 ubiquitination o |
0.789 |
7 |
7 |
— |
2026-04-21 |
| How does P2RY12-mediated VSMC dysfunction con |
0.623 |
7 |
3 |
— |
2026-04-21 |
| How can AQP4 be effectively targeted therapeu |
0.760 |
7 |
7 |
— |
2026-04-21 |
| Do microglia actually switch between glycolyt |
0.655 |
7 |
4 |
— |
2026-04-21 |
| What is the optimal therapeutic window during |
0.684 |
7 |
5 |
— |
2026-04-21 |
| What determines the specificity of TDP-43-ind |
0.734 |
7 |
5 |
— |
2026-04-21 |
| How does APOE4 mechanistically increase TDP-4 |
0.610 |
7 |
2 |
— |
2026-04-21 |
| What determines the specificity of RNA-protei |
0.763 |
7 |
7 |
— |
2026-04-21 |
| What determines P2RY12 receptor expression/ac |
0.661 |
7 |
4 |
— |
2026-04-21 |
| What causes IBA1 low/negative microglia in li |
0.760 |
7 |
7 |
— |
2026-04-21 |
| What are the specific molecular mechanisms by |
0.757 |
7 |
6 |
— |
2026-04-21 |
| Do perinatal immune challenges create persist |
0.706 |
7 |
6 |
— |
2026-04-21 |
| Which tau propagation mechanism predominates |
0.662 |
6 |
6 |
— |
2026-04-21 |
| What is the optimal therapeutic window timing |
0.780 |
7 |
7 |
— |
2026-04-21 |
| What are the specific molecular mechanisms by |
0.706 |
7 |
6 |
— |
2026-04-21 |
| What determines the selectivity of complement |
0.754 |
7 |
6 |
— |
2026-04-21 |
| How do different organelle-specific autophagy |
0.800 |
7 |
7 |
— |
2026-04-21 |
| How does chronic cGAS/STING activation downst |
0.730 |
6 |
4 |
— |
2026-04-21 |
| What determines the specificity of calcium-de |
0.731 |
4 |
3 |
— |
2026-04-21 |
| What mechanisms drive TDP-43 pathology specif |
0.697 |
3 |
2 |
— |
2026-04-21 |
| What molecular mechanisms determine the confo |
0.650 |
0 |
0 |
— |
2026-04-21 |
| What mechanisms underlie neuronal resistance |
0.650 |
5 |
4 |
— |
2026-04-21 |
| What determines the spatial organization of a |
0.691 |
5 |
3 |
— |
2026-04-21 |
| How does sevoflurane-induced NF-κB activation |
0.740 |
5 |
5 |
— |
2026-04-21 |
| What upstream mechanisms cause TDP-43 to trig |
0.772 |
5 |
4 |
— |
2026-04-21 |
| Why do structurally diverse sugars (trehalose |
0.597 |
3 |
0 |
— |
2026-04-21 |
| What specific astrocyte-derived factors can ' |
0.650 |
5 |
4 |
— |
2026-04-21 |
| How can CNS-selective HDAC/DNMT inhibitors be |
0.723 |
3 |
3 |
— |
2026-04-21 |
| What mechanisms underlie TDP-43's contributio |
0.734 |
5 |
4 |
— |
2026-04-21 |
| What are the neuron-specific effects of ALS-c |
0.812 |
4 |
4 |
— |
2026-04-21 |
| Investigate mechanisms of epigenetic reprogra |
0.500 |
3 |
3 |
— |
2026-04-21 |
| What are the specific pathophysiological mech |
0.655 |
2 |
1 |
— |
2026-04-21 |
| What determines organelle-specific autophagy |
0.655 |
2 |
1 |
— |
2026-04-21 |
| How can subcellular compartmentalization defe |
0.650 |
5 |
4 |
— |
2026-04-21 |
| What are the conserved secondary structures i |
0.688 |
5 |
3 |
— |
2026-04-21 |
| Do chaperones selectively recognize pathologi |
0.728 |
5 |
4 |
— |
2026-04-21 |
| What physicochemical properties determine sel |
0.713 |
3 |
3 |
— |
2026-04-21 |
| Investigate mechanisms of epigenetic reprogra |
0.417 |
0 |
0 |
— |
2026-04-21 |
| Investigate mechanisms of epigenetic reprogra |
0.500 |
0 |
0 |
— |
2026-04-21 |
| Investigate mechanisms of epigenetic reprogra |
0.558 |
0 |
0 |
— |
2026-04-21 |
| Investigate mechanisms of epigenetic reprogra |
0.481 |
0 |
0 |
— |
2026-04-21 |
| Investigate mechanisms of epigenetic reprogra |
0.506 |
0 |
0 |
— |
2026-04-21 |
| Investigate mechanisms of epigenetic reprogra |
0.730 |
7 |
6 |
— |
2026-04-21 |
| Investigate mechanisms of epigenetic reprogra |
0.517 |
0 |
0 |
— |
2026-04-21 |
| Mechanistic validation of SEA-AD differential |
0.661 |
0 |
0 |
— |
2026-04-21 |
| Investigate mechanisms of epigenetic reprogra |
0.584 |
0 |
0 |
— |
2026-04-21 |
| Mechanistic validation of SEA-AD differential |
0.639 |
0 |
0 |
— |
2026-04-21 |
| Do these mechanistic hypotheses explain layer |
0.300 |
0 |
0 |
— |
2026-04-21 |
| Do these mechanistic hypotheses from the SEA- |
0.300 |
7 |
6 |
— |
2026-04-21 |
| Do stellate neurons express unique α7 nicotin |
0.300 |
0 |
0 |
— |
2026-04-21 |
| Do tau strains or regional cellular environme |
0.300 |
7 |
2 |
— |
2026-04-21 |
| What are the specific design principles for s |
0.430 |
7 |
3 |
— |
2026-04-21 |
| Can circadian interventions selectively targe |
0.300 |
7 |
5 |
— |
2026-04-21 |
| Do different priming stimuli create distinct |
0.300 |
7 |
6 |
— |
2026-04-21 |
| Do tau-specific HSP90 conformational states e |
0.300 |
7 |
5 |
— |
2026-04-21 |
| Do tau-containing vesicles exhibit distinct s |
0.300 |
7 |
4 |
— |
2026-04-21 |
| Which specific post-translational modificatio |
0.300 |
7 |
2 |
— |
2026-04-21 |
| Which specific post-translational modificatio |
0.300 |
7 |
3 |
— |
2026-04-21 |
| Does tau aggregation specifically cause PS ex |
0.440 |
7 |
1 |
— |
2026-04-21 |
| Does tau aggregation specifically cause PS ex |
0.300 |
7 |
2 |
— |
2026-04-21 |
| What are the optimal temporal windows for TRE |
0.300 |
7 |
3 |
— |
2026-04-21 |
| What are the optimal timing windows for TREM2 |
0.300 |
7 |
3 |
— |
2026-04-21 |
| Does TFEB activation directly restore mutant |
0.300 |
0 |
0 |
— |
2026-04-21 |
| What are the specific molecular mechanisms li |
0.300 |
7 |
2 |
— |
2026-04-21 |
| Which specific metabolic pathways in APOE4 mi |
0.480 |
7 |
5 |
— |
2026-04-21 |
| Do SPM receptors undergo desensitization with |
0.300 |
7 |
5 |
— |
2026-04-21 |
| Metabolomic signatures of neurodegeneration a |
0.300 |
7 |
6 |
— |
2026-04-21 |
| Does SYK activation provide neuroprotection o |
0.300 |
0 |
0 |
— |
2026-04-21 |
| Spatial Transcriptomics Analysis of Alzheimer |
0.700 |
0 |
0 |
— |
2026-04-21 |
| Gene Co-expression Network Analysis of AD Pro |
0.700 |
0 |
0 |
— |
2026-04-21 |
| Cell-Cell Communication Analysis in AD Brain |
0.700 |
0 |
0 |
— |
2026-04-21 |
| Cas13 gRNA Design for Silencing MAPT (Tau) Tr |
0.700 |
0 |
0 |
— |
2026-04-21 |
| Proteomics Differential Expression in AD CSF |
0.700 |
0 |
0 |
— |
2026-04-21 |
| Multi-modal Biomarker Panel Design for Early |
0.700 |
0 |
0 |
— |
2026-04-21 |
| Clinical Trial Landscaping for Alzheimer's Di |
0.700 |
0 |
0 |
— |
2026-04-21 |
| De Novo Binder Design Targeting Alpha-Synucle |
0.700 |
0 |
0 |
— |
2026-04-21 |
| Survival Analysis of AD Patient Cohorts: Prog |
0.700 |
0 |
0 |
— |
2026-04-21 |
| Polygenic Risk Score Analysis for Late-Onset |
0.700 |
7 |
2 |
— |
2026-04-21 |
| Variant Annotation and Prioritization of AD R |
0.700 |
7 |
5 |
— |
2026-04-21 |
| Statistical Fine-Mapping of AD GWAS Loci to I |
0.700 |
7 |
3 |
— |
2026-04-21 |
| Gene Regulatory Network Inference in Alzheime |
0.700 |
7 |
5 |
— |
2026-04-21 |
| scRNA-seq Processing and Cell Type Annotation |
0.700 |
7 |
5 |
— |
2026-04-21 |
| Gut Microbiome Analysis in Parkinson's Diseas |
0.700 |
7 |
5 |
— |
2026-04-21 |
| Does Alectinib truly bind C1q directly with h |
0.500 |
3 |
3 |
— |
2026-04-21 |
| Does TRPML1 enhancement cause therapeutic ben |
0.720 |
3 |
3 |
— |
2026-04-21 |
| What evidence supports Cdk5 activation as THE |
0.500 |
0 |
0 |
— |
2026-04-21 |
| Do migratory animals encode specific spatial |
0.700 |
0 |
0 |
— |
2026-04-21 |
| What is the optimal BBB opening duration and |
0.500 |
0 |
0 |
— |
2026-04-21 |
| Does structural 'normalization' of APOE4 doma |
0.430 |
0 |
0 |
— |
2026-04-21 |
| Do circadian disruptions cause neurodegenerat |
0.500 |
0 |
0 |
— |
2026-04-21 |
| What distinguishes truly senescent brain cell |
0.500 |
0 |
0 |
— |
2026-04-21 |
| What brain concentrations of SCFAs are achiev |
0.500 |
0 |
0 |
— |
2026-04-21 |
| What is the therapeutic window between GCS in |
0.500 |
0 |
0 |
— |
2026-04-21 |
| Do chronic stress granule inhibition strategi |
0.500 |
0 |
0 |
— |
2026-04-21 |
| Can pathological vs physiological C1q tagging |
0.510 |
0 |
0 |
— |
2026-04-21 |
| Do transferred mitochondria from diseased ast |
0.500 |
0 |
0 |
— |
2026-04-21 |
| Can TREM2 receptor switching from agonism to |
0.500 |
0 |
0 |
— |
2026-04-21 |
| Do PINK1/PARKIN pathway enhancements rescue e |
0.500 |
0 |
0 |
— |
2026-04-21 |
| Which cell-type vulnerability signatures from |
0.500 |
0 |
0 |
— |
2026-04-21 |
| Do PINK1/PARKIN pathway enhancements rescue e |
0.500 |
0 |
0 |
— |
2026-04-21 |
| Are autophagy-lysosome defects primary driver |
0.500 |
0 |
0 |
— |
2026-04-21 |
| Does TFEB dysfunction causally drive neurodeg |
0.500 |
0 |
0 |
— |
2026-04-21 |
| What delivery mechanisms can achieve therapeu |
0.500 |
0 |
0 |
— |
2026-04-21 |
| Comparative epigenetic signatures: DNA methyl |
1.000 |
7 |
4 |
— |
2026-04-21 |
| Which neural cell types exhibit the most pron |
1.000 |
7 |
2 |
— |
2026-04-21 |
| What is the optimal ketone dosing threshold t |
1.000 |
7 |
1 |
— |
2026-04-21 |
| What validated biomarkers can determine optim |
1.000 |
7 |
6 |
— |
2026-04-21 |
| Does CXCL10 inhibition compromise CNS immune |
1.000 |
7 |
1 |
— |
2026-04-21 |
| Is myelin loss in AD causal or an adaptive re |
1.000 |
7 |
2 |
— |
2026-04-21 |
| Do P2RX7 antagonists selectively block pathog |
1.000 |
7 |
7 |
— |
2026-04-20 |
| Do tau aggregates represent protective respon |
1.000 |
7 |
3 |
— |
2026-04-20 |
| Do oligodendrocytes require DNA repair enhanc |
1.000 |
7 |
2 |
— |
2026-04-20 |
| Comparative epigenetic signatures: DNA methyl |
1.000 |
7 |
1 |
— |
2026-04-20 |
| Analyze the spectrum of microglial activation |
0.500 |
7 |
6 |
— |
2026-04-20 |
| Tau propagation mechanisms and therapeutic in |
0.500 |
0 |
0 |
— |
2026-04-20 |
| Does Alectinib truly bind C1q directly with h |
1.000 |
7 |
1 |
— |
2026-04-19 |
| Can P16INK4A expression reliably distinguish |
0.500 |
0 |
0 |
— |
2026-04-18 |
| How can CRISPR systems achieve persistent the |
0.500 |
7 |
3 |
— |
2026-04-18 |
| What are the optimal timing windows for TREM2 |
0.500 |
0 |
0 |
— |
2026-04-18 |
| How can circuit-level neurodegeneration mecha |
0.500 |
7 |
7 |
— |
2026-04-18 |
| Which specific aging-related gene expression |
0.500 |
0 |
0 |
— |
2026-04-18 |
| Which specific cell types show greatest vulne |
0.500 |
0 |
0 |
— |
2026-04-18 |
| What specific gene expression signatures in a |
0.500 |
0 |
0 |
— |
2026-04-18 |
| How can Allen Aging Mouse Brain Atlas data be |
0.500 |
0 |
0 |
— |
2026-04-18 |
| What specific gene expression signatures in a |
0.500 |
7 |
5 |
— |
2026-04-18 |
| What are the molecular signatures that distin |
0.490 |
7 |
3 |
— |
2026-04-18 |
| What is the temporal sequence of sleep disrup |
0.500 |
7 |
5 |
— |
2026-04-18 |
| Can biased TREM2 agonists selectively activat |
0.500 |
7 |
2 |
— |
2026-04-18 |
| What is the high-resolution structure of the |
0.500 |
7 |
0 |
— |
2026-04-18 |
| What are the molecular determinants that cont |
0.500 |
7 |
3 |
— |
2026-04-18 |
| Quantitative proteomics of the aging synapse: |
0.500 |
7 |
0 |
— |
2026-04-18 |
| Metabolomic signatures of neurodegeneration: |
0.500 |
0 |
0 |
— |
2026-04-18 |
| Lipid metabolism dysregulation in Alzheimer's |
0.500 |
0 |
0 |
— |
2026-04-18 |
| Systemic immune profiling in neurodegeneratio |
0.500 |
0 |
0 |
— |
2026-04-18 |
| Human connectome alterations in Alzheimer's d |
0.500 |
0 |
0 |
— |
2026-04-18 |
| Why have numerous phase 3 clinical trials fai |
0.500 |
7 |
1 |
— |
2026-04-18 |
| Comparative epigenetic signatures across AD, |
0.500 |
0 |
0 |
— |
2026-04-18 |
| Does RGS6 upregulation or D2 autoreceptor mod |
0.500 |
0 |
0 |
— |
2026-04-18 |
| Analyze the spectrum of microglial activation |
0.500 |
0 |
0 |
— |
2026-04-18 |
| Microglial subtypes in neurodegeneration — fr |
0.500 |
0 |
0 |
— |
2026-04-18 |
| Does RGS6 upregulation or D2 autoreceptor mod |
0.500 |
0 |
0 |
— |
2026-04-18 |
| Does Alectinib truly bind C1q directly with h |
0.500 |
7 |
4 |
— |
2026-04-18 |
| Neuroinflammation Biomarker Panel for Early A |
0.500 |
0 |
0 |
— |
2026-04-18 |
| Is ferroptosis the primary driver of motor ne |
0.500 |
4 |
0 |
— |
2026-04-18 |
| How do different microglial subtypes (DAM vs |
1.000 |
3 |
3 |
— |
2026-04-18 |
| Ferroptosis in ALS and motor neuron disease: |
0.589 |
7 |
0 |
— |
2026-04-17 |
| Gut Microbiome Analysis in Parkinson's Diseas |
0.700 |
2 |
1 |
— |
2026-04-16 |
| scRNA-seq Processing and Cell Type Annotation |
0.700 |
2 |
1 |
— |
2026-04-16 |
| Gene Regulatory Network Inference in Alzheime |
0.700 |
2 |
1 |
— |
2026-04-16 |
| Statistical Fine-Mapping of AD GWAS Loci to I |
0.700 |
2 |
1 |
— |
2026-04-16 |
| Variant Annotation and Prioritization of AD R |
0.700 |
2 |
1 |
— |
2026-04-16 |
| Polygenic Risk Score Analysis for Late-Onset |
0.700 |
2 |
1 |
— |
2026-04-16 |
| Survival Analysis of AD Patient Cohorts: Prog |
0.700 |
2 |
1 |
— |
2026-04-16 |
| Clinical Trial Landscaping for Alzheimer's Di |
0.700 |
2 |
1 |
— |
2026-04-16 |
| Proteomics Differential Expression in AD CSF |
0.700 |
2 |
1 |
— |
2026-04-16 |
| Cas13 gRNA Design for Silencing MAPT (Tau) Tr |
0.700 |
2 |
1 |
— |
2026-04-16 |
| De Novo Binder Design Targeting Alpha-Synucle |
0.700 |
2 |
1 |
— |
2026-04-16 |
| Multi-modal Biomarker Panel Design for Early |
0.700 |
2 |
1 |
— |
2026-04-16 |
| Cell-Cell Communication Analysis in AD Brain |
0.700 |
2 |
1 |
— |
2026-04-16 |
| Gene Co-expression Network Analysis of AD Pro |
0.700 |
2 |
1 |
— |
2026-04-16 |
| Spatial Transcriptomics Analysis of Alzheimer |
0.700 |
2 |
1 |
— |
2026-04-16 |
| test |
0.650 |
0 |
0 |
— |
2026-04-16 |
| Do β-amyloid plaques and neurofibrillary tang |
0.950 |
7 |
5 |
— |
2026-04-16 |
| How does Alectinib, a kinase inhibitor, achie |
0.940 |
7 |
0 |
— |
2026-04-16 |
| Senescent cell clearance as neurodegeneration |
0.750 |
3 |
3 |
— |
2026-04-16 |
| Is APOE4's reduced lipid binding pathogenic o |
0.710 |
3 |
2 |
— |
2026-04-16 |
| Does LRRK2's role as a lysosomal volume senso |
0.850 |
3 |
3 |
— |
2026-04-16 |
| What amyloid threshold level is required for |
0.760 |
3 |
3 |
— |
2026-04-16 |
| How do gut microbiome-derived metabolites SCF |
0.840 |
3 |
3 |
— |
2026-04-16 |
| What are the specific PTM changes in synaptic |
0.730 |
3 |
3 |
— |
2026-04-16 |
| Why have anti-Aβ clinical trials failed despi |
0.650 |
3 |
3 |
— |
2026-04-16 |
| Is C1q elevation in AD pathogenic or compensa |
0.580 |
0 |
0 |
— |
2026-04-16 |
| What determines the temporal transition from |
0.860 |
0 |
0 |
— |
2026-04-16 |
| Does DNAJB6 directly inhibit cross-seeding be |
0.790 |
3 |
0 |
— |
2026-04-16 |
| Is HCN1 dysfunction causal or protective in E |
0.930 |
6 |
2 |
— |
2026-04-16 |
| Does human glymphatic function show clinicall |
0.950 |
6 |
4 |
— |
2026-04-16 |
| Does TRPML1 enhancement cause therapeutic ben |
0.460 |
0 |
0 |
— |
2026-04-16 |
| How can functional hyperconnectivity patterns |
0.950 |
7 |
5 |
— |
2026-04-16 |
| Do astrocytes functionally express TRIM46, an |
0.950 |
7 |
7 |
— |
2026-04-16 |
| What mechanisms explain how IDH1/IDH2 mutatio |
0.950 |
7 |
1 |
— |
2026-04-16 |
| What molecular mechanisms drive neuron-to-gli |
0.620 |
0 |
0 |
— |
2026-04-16 |
| Why does PGC-1α overexpression paradoxically |
0.700 |
0 |
0 |
— |
2026-04-16 |
| How does PSEN2 mechanistically regulate α-syn |
0.680 |
0 |
0 |
— |
2026-04-16 |
| What molecular mechanisms explain how KCNJ2 i |
0.710 |
0 |
0 |
— |
2026-04-16 |
| Why do TAM receptors protect against neuroinv |
0.740 |
0 |
0 |
— |
2026-04-16 |
| What signals trigger microglia to specificall |
0.700 |
0 |
0 |
— |
2026-04-16 |
| What are the molecular mechanisms by which GL |
0.950 |
7 |
2 |
— |
2026-04-16 |
| How does pericyte senescence mechanistically |
0.950 |
7 |
7 |
— |
2026-04-16 |
| Why does Metformin fail to delay CJD progress |
0.680 |
0 |
0 |
— |
2026-04-16 |
| What molecular mechanisms enable Gal3 to enha |
0.920 |
7 |
3 |
— |
2026-04-16 |
| What molecular mechanisms mediate HDAC9's eff |
0.950 |
7 |
0 |
— |
2026-04-16 |
| What molecular mechanisms cause iPLA2β defici |
0.950 |
7 |
3 |
— |
2026-04-16 |
| What determines the GPX4/ACSL4 balance that s |
0.800 |
7 |
4 |
— |
2026-04-16 |
| Are age-related static epigenetic patterns pa |
0.950 |
7 |
3 |
— |
2026-04-16 |
| How do synthetic EVs achieve brain-specific t |
0.500 |
0 |
0 |
— |
2026-04-16 |
| test debate |
0.950 |
7 |
4 |
— |
2026-04-16 |
| Does APOE4 drive tau propagation |
0.640 |
0 |
0 |
— |
2026-04-16 |
| Blood-brain barrier tight junction disruption |
0.870 |
7 |
3 |
— |
2026-04-16 |
| Does APOE4 drive tau propagation |
0.680 |
0 |
0 |
— |
2026-04-16 |
| What genetic risk factors predispose individu |
0.580 |
0 |
0 |
— |
2026-04-16 |
| Why do p300/CBP inhibitors reduce both AD inc |
0.950 |
7 |
0 |
— |
2026-04-16 |
| How does FUS loss-of-function in TAZ regulati |
0.810 |
5 |
5 |
— |
2026-04-16 |
| How does APOE4's beneficial immune function r |
0.600 |
0 |
0 |
— |
2026-04-16 |
| What specific molecular mechanisms link APOE4 |
0.690 |
3 |
3 |
— |
2026-04-16 |
| Does clusterin exacerbate or protect against |
0.720 |
3 |
3 |
— |
2026-04-16 |
| Do CXCL10-recruited CD8+ T cells provide neur |
0.760 |
3 |
3 |
— |
2026-04-16 |
| Are interneuron oscillation deficits compensa |
0.760 |
3 |
3 |
— |
2026-04-16 |
| What are the cell-type-specific transcriptomi |
0.760 |
3 |
3 |
— |
2026-04-16 |
| How do sphingomyelin/ceramide ratios specific |
0.840 |
3 |
2 |
— |
2026-04-16 |
| What molecular mechanisms mediate HDAC9's eff |
0.710 |
3 |
3 |
— |
2026-04-16 |
| Why does autophagy inhibition improve neurona |
0.740 |
3 |
3 |
— |
2026-04-16 |
| What molecular mechanisms explain how apoE pr |
0.710 |
3 |
3 |
— |
2026-04-16 |
| What molecular mechanisms link elevated sphin |
0.750 |
3 |
3 |
— |
2026-04-16 |
| How does SYNGAP1, a 'synaptic' protein, funct |
0.780 |
3 |
3 |
— |
2026-04-16 |
| What upstream mechanisms trigger p53 activati |
0.610 |
3 |
3 |
— |
2026-04-16 |
| What are the physiological functions of BACE1 |
0.760 |
3 |
3 |
— |
2026-04-16 |
| How do ALS-associated OPTN mutations mechanis |
0.950 |
7 |
3 |
— |
2026-04-16 |
| How do P/Q channel deficits paradoxically inc |
0.950 |
7 |
0 |
— |
2026-04-16 |
| How does engineered C. butyricum cross the bl |
0.950 |
7 |
5 |
— |
2026-04-16 |
| Why does iron chelation therapy worsen outcom |
0.950 |
7 |
7 |
— |
2026-04-16 |
| Why does PRKN-mediated mitophagy, typically p |
0.910 |
7 |
4 |
— |
2026-04-16 |
| What molecular mechanisms drive the transitio |
0.830 |
7 |
5 |
— |
2026-04-16 |
| Should microtubule-stabilizing drugs be recon |
0.680 |
0 |
0 |
— |
2026-04-16 |
| What are the specific molecular determinants |
0.570 |
0 |
0 |
— |
2026-04-16 |
| What is the temporal sequence of TREM2 signal |
0.730 |
4 |
4 |
— |
2026-04-16 |
| Why is TYROBP deficiency neuroprotective when |
0.560 |
0 |
0 |
— |
2026-04-16 |
| What are the specific circulating factors in |
0.950 |
7 |
4 |
— |
2026-04-16 |
| What molecular mechanisms determine whether r |
0.660 |
0 |
0 |
— |
2026-04-16 |
| Metabolic reprogramming in neurodegenerative |
0.950 |
7 |
7 |
— |
2026-04-16 |
| What molecular mechanisms enable functional r |
0.850 |
7 |
4 |
— |
2026-04-16 |
| Why does the V1613M variant reduce amyloid pa |
0.600 |
0 |
0 |
— |
2026-04-16 |
| Why do TAM receptors protect against neuroinv |
0.750 |
0 |
0 |
— |
2026-04-16 |
| What are the precise temporal dynamics of ast |
0.850 |
3 |
3 |
— |
2026-04-15 |
| What molecular mechanisms mediate SPP1-induce |
0.950 |
7 |
3 |
— |
2026-04-15 |
| How do the seven novel ALS genes function in |
0.710 |
3 |
3 |
— |
2026-04-14 |
| What is the atomic-resolution structure of K2 |
0.860 |
3 |
3 |
— |
2026-04-14 |
| What is the atomic-resolution structure of K2 |
0.740 |
3 |
3 |
— |
2026-04-14 |
| What are the specific molecular mechanisms by |
0.780 |
3 |
3 |
— |
2026-04-14 |
| What are the specific molecular mechanisms by |
0.670 |
3 |
3 |
— |
2026-04-14 |
| What molecular mechanisms underlie Atremorine |
0.670 |
3 |
3 |
— |
2026-04-14 |
| What molecular mechanisms underlie the dose-d |
0.810 |
3 |
3 |
— |
2026-04-14 |
| What molecular mechanisms enable microglia to |
0.680 |
3 |
3 |
— |
2026-04-14 |
| What molecular mechanisms enable microglia to |
0.620 |
3 |
3 |
— |
2026-04-14 |
| What molecular mechanisms enable microglia to |
0.920 |
3 |
3 |
— |
2026-04-14 |
| Does TRT-induced erythrocytosis actually incr |
0.830 |
3 |
3 |
— |
2026-04-14 |
| What is the molecular mechanism by which olig |
0.780 |
3 |
3 |
— |
2026-04-14 |
| What is the molecular mechanism by which olig |
0.820 |
3 |
3 |
— |
2026-04-14 |
| What molecular mechanism causes VCP mutations |
0.780 |
3 |
3 |
— |
2026-04-14 |
| How do oligodendrocytes initiate neuroinflamm |
0.790 |
3 |
3 |
— |
2026-04-14 |
| How do B cells mechanistically orchestrate to |
0.660 |
3 |
3 |
— |
2026-04-14 |
| How does PIKFYVE inhibition activate unconven |
0.630 |
0 |
0 |
— |
2026-04-14 |
| How do B cells mechanistically orchestrate to |
0.790 |
3 |
3 |
— |
2026-04-14 |
| How does HDAC1/2 deletion specifically enhanc |
0.950 |
7 |
2 |
— |
2026-04-14 |
| Which tau PTMs are both disease-specific and |
0.650 |
0 |
0 |
— |
2026-04-13 |
| RNA binding protein dysregulation across ALS |
0.500 |
0 |
0 |
— |
2026-04-13 |
| What determines blood-brain barrier penetrati |
0.660 |
0 |
0 |
— |
2026-04-13 |
| Unable to extract research questions - transc |
0.950 |
7 |
2 |
— |
2026-04-13 |
| What is the therapeutic window between insuff |
0.820 |
3 |
3 |
— |
2026-04-13 |
| What is the relative contribution of connexin |
0.740 |
3 |
3 |
— |
2026-04-13 |
| Why have anti-Aβ clinical trials failed despi |
0.700 |
3 |
3 |
— |
2026-04-13 |
| Do β-amyloid plaques and neurofibrillary tang |
0.790 |
3 |
3 |
— |
2026-04-13 |
| Do SCFAs directly modulate α-synuclein aggreg |
0.700 |
3 |
3 |
— |
2026-04-13 |
| How do neurodegeneration gene expression patt |
0.700 |
3 |
3 |
— |
2026-04-13 |
| How does APOE4's beneficial immune function r |
0.780 |
3 |
3 |
— |
2026-04-13 |
| Which metabolic biomarkers can distinguish th |
0.770 |
3 |
3 |
— |
2026-04-13 |
| Why have numerous phase 3 clinical trials fai |
0.670 |
3 |
3 |
— |
2026-04-12 |
| How do astrocyte-neuron metabolic interaction |
0.860 |
3 |
3 |
— |
2026-04-12 |
| Quantitative proteomics of the aging synapse |
0.680 |
3 |
3 |
— |
2026-04-12 |
| Systemic immune profiling and peripheral immu |
0.760 |
3 |
3 |
— |
2026-04-12 |
| Systemic immune profiling and peripheral immu |
0.780 |
3 |
3 |
— |
2026-04-12 |
| Human connectome alterations and network-leve |
0.710 |
3 |
3 |
— |
2026-04-12 |
| Which specific post-translational modificatio |
0.840 |
3 |
3 |
— |
2026-04-12 |
| Which specific post-translational modificatio |
0.710 |
3 |
3 |
— |
2026-04-12 |
| Tau propagation mechanisms and therapeutic in |
0.900 |
3 |
3 |
— |
2026-04-12 |
| Mitochondrial transfer between neurons and gl |
0.710 |
3 |
3 |
— |
2026-04-12 |
| Protein aggregation cross-seeding across neur |
0.700 |
3 |
3 |
— |
2026-04-12 |
| Extracellular vesicle biomarkers for early AD |
0.750 |
3 |
3 |
— |
2026-04-12 |
| 4R-tau strain-specific spreading patterns in |
0.690 |
3 |
3 |
— |
2026-04-12 |
| RNA binding protein dysregulation across ALS |
0.720 |
3 |
3 |
— |
2026-04-12 |
| Do bacterial curli amyloids cross the blood-b |
0.840 |
3 |
3 |
— |
2026-04-12 |
| Neuroinflammation and microglial priming in e |
0.800 |
3 |
3 |
— |
2026-04-12 |
| Neuroinflammation and microglial priming in e |
0.860 |
4 |
3 |
— |
2026-04-12 |
| Neuroinflammation and microglial priming in e |
0.950 |
7 |
5 |
— |
2026-04-12 |
| What is the actual quantitative contribution |
0.910 |
7 |
3 |
— |
2026-04-12 |
| TDP-43 phase separation therapeutics for ALS- |
0.840 |
7 |
5 |
— |
2026-04-12 |
| Does reduced Prevotellaceae abundance cause P |
0.950 |
7 |
1 |
— |
2026-04-11 |
| Lipid raft composition changes in synaptic ne |
0.930 |
7 |
6 |
— |
2026-04-11 |
| TDP-43 phase separation therapeutics for ALS- |
0.950 |
7 |
2 |
— |
2026-04-11 |
| Lipid metabolism dysregulation and membrane i |
0.840 |
6 |
6 |
— |
2026-04-11 |
| Systemic immune profiling and peripheral immu |
0.500 |
0 |
0 |
— |
2026-04-11 |
| Human connectome alterations and network-leve |
0.440 |
0 |
0 |
— |
2026-04-11 |
| Quantitative proteomics of the aging synapse |
0.560 |
0 |
0 |
— |
2026-04-11 |
| Epigenetic reprogramming in aging neurons |
0.950 |
7 |
3 |
— |
2026-04-10 |
| What molecular mechanisms drive tissue-specif |
0.950 |
7 |
4 |
— |
2026-04-10 |
| How do protein-protein interactions determine |
0.950 |
7 |
1 |
— |
2026-04-10 |
| How do dilncRNAs specifically drive molecular |
0.900 |
7 |
4 |
— |
2026-04-10 |
| How do host cell factors influence the confor |
0.950 |
7 |
3 |
— |
2026-04-10 |
| What determines the specificity of DDR protei |
0.950 |
7 |
1 |
— |
2026-04-10 |
| Gut-Brain Axis Therapeutics for Alzheimer's D |
0.940 |
7 |
4 |
— |
2026-04-10 |
| Selective vulnerability of entorhinal cortex |
0.950 |
7 |
4 |
— |
2026-04-10 |
| 4R-tau strain-specific spreading patterns in |
0.910 |
7 |
2 |
— |
2026-04-10 |
| How do non-cell autonomous effects of autopha |
0.940 |
7 |
4 |
— |
2026-04-10 |
| Can circadian interventions reverse microglia |
0.950 |
7 |
5 |
— |
2026-04-10 |
| Do different priming stimuli require distinct |
0.930 |
7 |
5 |
— |
2026-04-10 |
| What are the minimal structural requirements |
0.860 |
7 |
2 |
— |
2026-04-10 |
| Do tau-containing vesicles exhibit unique sur |
0.950 |
7 |
0 |
— |
2026-04-10 |
| Which specific post-translational modificatio |
0.500 |
0 |
0 |
— |
2026-04-10 |
| Can nanobodies achieve selective membrane pen |
0.950 |
7 |
4 |
— |
2026-04-10 |
| TREM2 Therapeutic Strategy Post-INVOKE-2 |
0.950 |
7 |
2 |
— |
2026-04-10 |
| Astrocyte reactivity subtypes in neurodegener |
0.950 |
7 |
3 |
— |
2026-04-10 |
| GBA-Synuclein Loop: Therapeutic Strategies fo |
0.890 |
7 |
4 |
— |
2026-04-10 |
| Why do systemic anti-inflammatory drugs fail |
0.790 |
7 |
6 |
— |
2026-04-10 |
| How can ESCRT or SNARE targeting achieve tau- |
0.950 |
7 |
4 |
— |
2026-04-09 |
| Can metabolic interventions truly reverse est |
0.950 |
7 |
6 |
— |
2026-04-09 |
| How does SPI1 transcriptionally regulate C1QA |
0.930 |
7 |
4 |
— |
2026-04-09 |
| Why does prolonged anesthesia cause both cogn |
0.830 |
7 |
2 |
— |
2026-04-09 |
| What determines the selectivity and efficienc |
0.950 |
7 |
2 |
— |
2026-04-09 |
| How does ADCY8 mechanistically regulate long- |
0.950 |
7 |
7 |
— |
2026-04-09 |
| Which specific metabolic pathways in APOE4+ m |
0.920 |
7 |
5 |
— |
2026-04-09 |
| Why do clinical manifestations overlap despit |
0.860 |
7 |
6 |
— |
2026-04-09 |
| What neural circuits encode and maintain mult |
0.950 |
7 |
4 |
— |
2026-04-09 |
| Astrocyte Reactivity Subtypes in Neurodegener |
0.950 |
7 |
4 |
— |
2026-04-09 |
| Blood-brain barrier transport mechanisms for |
0.910 |
7 |
5 |
— |
2026-04-07 |
| Microglia-astrocyte crosstalk amplification l |
0.900 |
7 |
4 |
— |
2026-04-07 |
| APOE4 structural biology and therapeutic targ |
0.890 |
7 |
2 |
— |
2026-04-07 |
| Autophagy-lysosome pathway convergence across |
0.900 |
7 |
5 |
— |
2026-04-07 |
| Digital biomarkers and AI-driven early detect |
0.950 |
7 |
3 |
— |
2026-04-07 |
| Senolytic therapy for age-related neurodegene |
0.890 |
7 |
7 |
— |
2026-04-07 |
| Neuroinflammation resolution mechanisms and p |
0.830 |
7 |
4 |
— |
2026-04-07 |
| Mitochondrial transfer between neurons and gl |
0.810 |
7 |
0 |
— |
2026-04-07 |
| Protein aggregation cross-seeding across neur |
0.530 |
1 |
0 |
— |
2026-04-07 |
| Gut-Brain Axis Therapeutics for AD |
0.950 |
7 |
5 |
— |
2026-04-07 |
| GBA-Synuclein Loop Therapeutics for PD |
0.900 |
7 |
5 |
— |
2026-04-07 |
| TREM2 Therapeutic Strategy Post-INVOKE-2 |
0.950 |
7 |
5 |
— |
2026-04-07 |
| Mechanistic role of APOE in neurodegeneration |
0.870 |
3 |
3 |
— |
2026-04-07 |
| Sleep disruption as cause and consequence of |
0.910 |
7 |
4 |
— |
2026-04-07 |
| RNA binding protein dysregulation across ALS |
0.880 |
7 |
6 |
— |
2026-04-07 |
| Synaptic pruning by microglia in early AD |
0.950 |
7 |
3 |
— |
2026-04-07 |
| Mitochondrial transfer between astrocytes and |
0.950 |
7 |
3 |
— |
2026-04-07 |
| Epigenetic clocks and biological aging in neu |
0.930 |
7 |
6 |
— |
2026-04-07 |
| Perivascular spaces and glymphatic clearance |
0.950 |
7 |
7 |
— |
2026-04-07 |
| What are the mechanisms by which gut microbio |
0.950 |
7 |
4 |
— |
2026-04-07 |
| TREM2 Therapeutic Strategy Post-INVOKE-2 |
0.930 |
7 |
2 |
— |
2026-04-06 |
| Neuroinflammation and microglial priming in e |
0.950 |
7 |
0 |
— |
2026-04-04 |
| Tau propagation mechanisms and therapeutic in |
0.950 |
7 |
7 |
— |
2026-04-04 |
| Senescent cell clearance as neurodegeneration |
0.950 |
7 |
4 |
— |
2026-04-04 |
| SEA-AD Single-Cell Analysis: Cell-Type Vulner |
0.680 |
0 |
0 |
— |
2026-04-04 |
| SEA-AD Single-Cell Analysis: Cell-Type Vulner |
0.880 |
5 |
4 |
— |
2026-04-04 |
| Which metabolic biomarkers can distinguish th |
0.920 |
7 |
4 |
— |
2026-04-04 |
| How do neurodegeneration gene expression patt |
0.940 |
7 |
3 |
— |
2026-04-04 |
| How do astrocyte-neuron metabolic interaction |
0.930 |
7 |
4 |
— |
2026-04-04 |
| Which cell types show the most significant ex |
0.930 |
7 |
5 |
— |
2026-04-04 |
| What determines the optimal timing and dosing |
0.800 |
8 |
7 |
— |
2026-04-04 |
| Does TFEB dysfunction cause neurodegeneration |
0.950 |
7 |
5 |
— |
2026-04-04 |
| Gene expression changes in aging mouse brain |
0.950 |
7 |
6 |
— |
2026-04-04 |
| Gene expression changes in aging mouse brain |
0.950 |
6 |
5 |
— |
2026-04-04 |
| Gene expression changes in aging mouse brain |
0.950 |
6 |
5 |
— |
2026-04-04 |
| CRISPR-based therapeutic approaches for neuro |
0.950 |
7 |
5 |
— |
2026-04-04 |
| Immune atlas neuroinflammation analysis in ne |
0.850 |
7 |
7 |
— |
2026-04-04 |
| Cell type vulnerability in Alzheimer's Diseas |
0.920 |
7 |
3 |
— |
2026-04-04 |
| Circuit-level neural dynamics in neurodegener |
0.950 |
6 |
5 |
— |
2026-04-04 |
| Tau propagation mechanisms and therapeutic in |
0.950 |
7 |
3 |
— |
2026-04-04 |
| Cell type vulnerability in Alzheimers Disease |
0.900 |
7 |
3 |
— |
2026-04-03 |
| Cell type vulnerability in Alzheimers Disease |
0.950 |
7 |
5 |
— |
2026-04-03 |
| Cell type vulnerability in Alzheimer's Diseas |
0.950 |
6 |
3 |
— |
2026-04-03 |
| Cell type vulnerability in Alzheimer's Diseas |
0.950 |
7 |
7 |
— |
2026-04-03 |
| Metabolic reprogramming in neurodegenerative |
0.730 |
3 |
2 |
— |
2026-04-02 |
| Gene expression changes in aging mouse brain |
0.710 |
4 |
4 |
— |
2026-04-02 |
| Cell type vulnerability in Alzheimers Disease |
0.740 |
3 |
3 |
— |
2026-04-02 |
| Epigenetic reprogramming in aging neurons |
0.950 |
7 |
7 |
— |
2026-04-02 |
| Extracellular vesicle biomarkers for early AD |
0.870 |
7 |
6 |
— |
2026-04-02 |
| Tau propagation mechanisms and therapeutic in |
0.880 |
6 |
3 |
— |
2026-04-02 |
| Cell type vulnerability in Alzheimers Disease |
0.570 |
0 |
0 |
— |
2026-04-02 |
| Senescent cell clearance as neurodegeneration |
0.950 |
7 |
3 |
— |
2026-04-02 |
| CRISPR-based therapeutic approaches for neuro |
0.900 |
7 |
3 |
— |
2026-04-02 |
| TREM2 agonism vs antagonism in DAM microglia |
0.890 |
7 |
0 |
— |
2026-04-02 |
| Immune atlas neuroinflammation analysis in ne |
0.550 |
0 |
0 |
— |
2026-04-02 |
| Circuit-level neural dynamics in neurodegener |
0.420 |
0 |
0 |
— |
2026-04-02 |
| Gene expression changes in aging mouse brain |
0.430 |
0 |
0 |
— |
2026-04-02 |
| Cell type vulnerability in Alzheimer's Diseas |
0.560 |
0 |
0 |
— |
2026-04-02 |
| Gene expression changes in aging mouse brain |
0.500 |
0 |
0 |
— |
2026-04-02 |
| Gene expression changes in aging mouse brain |
0.570 |
0 |
0 |
— |
2026-04-02 |
| Gene expression changes in aging mouse brain |
0.560 |
1 |
1 |
— |
2026-04-02 |
| Microglial subtypes in neurodegeneration — fr |
0.490 |
0 |
0 |
— |
2026-04-02 |
| Is disrupted sleep a cause or consequence of |
0.590 |
0 |
0 |
— |
2026-04-02 |
| Is disrupted sleep a cause or consequence of |
0.460 |
0 |
0 |
— |
2026-04-02 |
| TREM2 agonism vs antagonism in DAM microglia |
0.570 |
7 |
7 |
— |
2026-04-02 |
| Selective vulnerability of entorhinal cortex |
0.920 |
7 |
5 |
— |
2026-04-01 |
| 4R-tau strain-specific spreading patterns in |
0.950 |
7 |
2 |
— |
2026-04-01 |
| TDP-43 phase separation therapeutics for ALS- |
0.950 |
7 |
7 |
— |
2026-04-01 |
| Astrocyte reactivity subtypes in neurodegener |
0.950 |
7 |
6 |
— |
2026-04-01 |
| Blood-brain barrier transport mechanisms for |
0.940 |
7 |
4 |
— |
2026-04-01 |
| Microglia-astrocyte crosstalk amplification l |
0.950 |
7 |
6 |
— |
2026-04-01 |
| APOE4 structural biology and therapeutic targ |
0.950 |
7 |
3 |
— |
2026-04-01 |
| Autophagy-lysosome pathway convergence across |
0.950 |
7 |
7 |
— |
2026-04-01 |
| Digital biomarkers and AI-driven early detect |
0.860 |
7 |
5 |
— |
2026-04-01 |
| Senolytic therapy for age-related neurodegene |
0.920 |
7 |
6 |
— |
2026-04-01 |
| Neuroinflammation resolution mechanisms and p |
0.950 |
7 |
6 |
— |
2026-04-01 |
| What are the mechanisms by which gut microbio |
0.950 |
20 |
11 |
— |
2026-04-01 |
| What are the mechanisms by which gut microbio |
0.890 |
7 |
4 |
— |
2026-04-01 |
| Mitochondrial transfer between neurons and gl |
0.810 |
7 |
0 |
— |
2026-04-01 |
| Protein aggregation cross-seeding across neur |
0.950 |
7 |
0 |
— |
2026-04-01 |
| Mechanistic role of APOE in neurodegeneration |
0.940 |
6 |
2 |
— |
2026-04-01 |
| Sleep disruption as cause and consequence of |
0.950 |
7 |
6 |
— |
2026-04-01 |
| RNA binding protein dysregulation across ALS |
0.920 |
7 |
5 |
— |
2026-04-01 |
| Synaptic pruning by microglia in early AD |
0.950 |
7 |
6 |
— |
2026-04-01 |
| Mitochondrial transfer between astrocytes and |
0.950 |
7 |
4 |
— |
2026-04-01 |
| Epigenetic clocks and biological aging in neu |
0.880 |
6 |
1 |
— |
2026-04-01 |
| Perivascular spaces and glymphatic clearance |
0.930 |
7 |
7 |
— |
2026-04-01 |